# Data for FY2007 are not yet available and thus, FY2006 data are used. 1. Arikian was paid $20,334 in other compensation which consisted of $10,406 related to medical, dental and life insurance and long and short term disability, $26,528 related to auto related expenses and $9,929 related to 401(k) matching contributions. 2. Other compensation includes accrued vacation time of $12,595 paid upon Fisher’s resignation in July 2007 and 401(k) match of $4,198. 3. Salary includes a payment of $24

# Data for FY2007 are not yet available and thus, FY2006 data are used. 1. Other compensation includes an employer retirement contribution of $63,758. 2. The fiscal year 2007 incentive compensation for Austin was calculated in U.S. dollars based on his annual salary of $240,000 prior to his transfer to the company’s U.K. office. 3. Other compensation represents $281 of life insurance premiums paid by Achillion and $7,958 in matching company contributions pursuant to Achillion’s 401(k) defined

# Data for FY2007 are not yet available and thus, FY2006 data are used. 1. Other compensation includes $855 of supplemental life insurance premium payments in 2007. 2. Tebbutt joined Alexza on March 12, 2007. Other compensation represents the reimbursement of $139,104 of relocation expenses and $20,114 of monthly housing supplements payments. 3. The amount of other compensation for Caruso consists of a $5,000 company contribution under the company’s 401(k) plan, offset by $1,300 in payments

# Data for FY2007 are not yet available and thus, FY2006 data are used. 1. Duffey was paid $38,864 in other compensation: $4,731 related to medical, dental and life insurance and long and short term disability; $6,000 related to auto allowances; and $28,133 related to unused vacation payout. 2. Other compensation represents $281 of life insurance premiums paid by Achillion and $7,590 in matching company contributions pursuant to Achillion’s 401(k) defined contribution plan. 3. In addition to

# Data for FY2007 are not yet available and thus, FY2006 data are used. 1. Other compensation includes $11,250 employer 401(k) matching and $855 of supplemental life insurance premium payments. 2. Other compensation represents a company 401(k) plan matching contribution of $1,563 and group term life insurance premiums of $1,161 paid on behalf of Russo. 3. Pearce was paid $50,112 in other compensation which consisted of payments related to medical, dental and life insurance and long and short

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options ($k) Stocks ($k) AASTROM BIOSCIENCES Gerald D. Brennan Jr. 230 - 230 27 156 414 - - ACADIA PHARMA Thomas H. Aasen1 285 68 354 12 124 491 119 - ACCELRYS Rick E. Russo2 273 64 337 2 77 269 - - ACCENTIA BIOPHARMA Alan M. Pearce3 260 25 285 50 663 999 - - ACCESS PHARMA Stephen B. Thompson 154 - 154 7 - 161 - - ACHILLION PHARMA Mary

For the 207 chief financial officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 David A. Ebersman GENENTECH INC 503 920 1,423 2 Paul J. Clancy BIOGEN IDEC INC 1,003 280 1,284 3 Robert A. Bradway AMGEN INC 664 545 1,209 4 John F. Milligan GILEAD SCIENCES INC 626 541 1,168 5 Michael S. Wyzga GENZYME CORP 489 560 1,049 6 B. Lynne Parshall ISIS PHARMACEUTICALS INC 484 543 1,027

Number of companies 218 Total number of employees >115,000 Average number of employees 535 Median number of employees 116 Total market capitalization $398.7 billion Average market capitalization $1.8 billion Median market capitalization $150.6 million Smallest market capitalization $1.2 million (Alliance Pharmaceutical Corp.) Largest market capitalization $99.8 billion (Genentech Inc.) Total shares outstanding 14.9 billion Average shares outstanding 58.9 million Median

Staff Writer Despite ground to be regained after a rough 2006 and the influence of broader economic woes in 2007, biotech stocks held up better than many sectors of the economy last year. Accordingly, top-level biotech execs as a whole saw their salaries and bonuses continue to climb, according to BioWorld’s 2009 Executive Compensation Report. Average cash compensation for CEOs rose to $597,000 in 2007 from $555,000 in 2006, and other executive-level positions saw similar gains. There were

The data presented in this book were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC) for fiscal year 2007. Important Notes The executives/officers listed for the 218 companies surveyed are the individual who held that title for the majority of the fiscal year reported. Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives

# Data for FY2007 are not yet available and thus, FY2006 data are used. 1. Other compensation includes $11,250 in employer 401(k) matching and $855 of supplemental life insurance premium payments. 2. Other compensation represents a company 401(k) plan matching contribution of $7,225 and group term life insurance premiums of $1,517 paid on behalf of Emkjer. 3. O’Donnell was paid $13,357 in other compensation, which consisted entirely of payments related to medical, dental and life insurance

Company Executive Base Salary ($k) Bonus ($k) Total ($k) Other ($k) Long- Term Comp. ($k) Total Direct Comp. ($k) Salary Prior FY ($k) Percent Change In Salary Options ($k) Stocks ($k) Stock Price 12/31/07 Shares Out (M) Market Cap ($M) Revenues ($M) AASTROM BIOSCIENCES George W. Dunbar 375 - 375 80 1,066 1,506 n/a n/a - - 0.52 120 49.1 0.7 ACADIA PHARMACEUTICALS Uli Hacksell1 439 116 555 12 285 852 420 4.5 - - 11.07 37 116 7.6 ACCELRYS Mark J

CEOs Whose Total Direct Compensation Exceeded $1 Million Executive Company Salary ($k) Bonus ($k) Other ($k) Long-Term Compensation ($k) Total Direct Compensation ($k) Martine A. Rothblatt UNITED THERAPEUTICS 767 225 247 23,756 24,996 Kevin W. Sharer AMGEN 1,547 1,530 894 15,941 19,912 Arthur D. Levinson GENENTECH 995 2,725 411 14,080 18,211 Henri A. Termeer GENZYME 1,503 2,142 105 10,880 14,631 Frank Baldino Jr. CEPHALON 1,196 2,213 76 10,021 13

Rank Executive Company Bonus ($k) Base Salary ($k) Bonus As Percentage Of Salary Other ($k) Stock Price 12/31/2007 Stock Price 12/29/2006 Percent Change In Stock Price 1 Arthur D. Levinson GENENTECH 2,725 995 273.9 411061 67.07 81.13 -17.3 2 Sol J. Barer CELGENE 2,248 833 269.8 181417 46.21 57.53 -19.7 3 Frank Baldino Jr. CEPHALON 2,213 1,196 185 76897 71.76 70.41 1.9 4 Henri A. Termeer GENZYME 2,142 1,503 142.5 105773 74.44 61.58 20.9

Rank Executive Company Salary ($k) Salary Prior FY ($k) Percent Change in Salary Stock Price 12/31/07 Stock Price 12/29/06 Percent Change in Stock Market Capitalization ($M) 1 Kevin W. Sharer AMGEN 1,547 1,482 4.4 46.44 68.31 -32 67,782 2 Henri A. Termeer GENZYME 1,503 1,431 5 74.44 61.58 20.9 20,334 3 Frank Baldino Jr. CEPHALON 1,196 1,129 5 71.76 70.41 1.9 5,016 4 James C. Mullen BIOGEN IDEC 1,142 1,084 5.3 56.92 49.19 15.7 20,686

For the 218 chief executive officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Name Salary ($k) Bonus ($k) Total ($k) 1 Arthur D. Levinson GENENTECH INC 995 2,725 3,720 2 Henri A. Termeer GENZYME CORP 1,503 2,142 3,645 3 Frank Baldino Jr. CEPHALON INC 1,196 2,213 3,410 4 James C. Mullen BIOGEN IDEC INC 1,142 1,943 3,085 5 Sol J. Barer CELGENE CORP /DE/ 833 2,248 3,081 6 Kevin W. Sharer AMGEN INC 1,547 1,530

Total: $594,000

Total: $614,000

Total: $608,000